Repligen Corp (RGEN) Price Targets From Analysts
Use the tables below to see what analysts covering Repligen Corp think about its future price and what recommendations they have for investors and traders.
|Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
RGEN Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for RGEN as an investment opportunity.
- The percent of analysts bearish on the stock of RGEN is less than almost 100% of all US stocks.
- RGEN has a greater average analyst price target than 97.9% of Pharmaceutical Products stocks.
- Repligen Corp's percentage of analysts bullish on the stock is greater than 93.69% of stocks in the large market cap category.
- Repligen Corp's number of analysts covering the stock is higher than 11.64% of stocks in the large market cap category.
- RGEN has a higher upside potential (average analyst target price relative to current price) than 81.12% of stocks in the large market cap category.
- The variance in analysts' estimates of RGEN is lower than 63.57% of Pharmaceutical Products stocks.
- Repligen Corp's change in bullishness amongst analysts is less than almost 100% of all US stocks.
What is the outlook for RGEN? Use POWR Ratings for clearer insight into price direction.